At a glance
- Originator Aventis
- Class Anti-ischaemics
- Mechanism of Action Nitric oxide donors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 04 Oct 1999 No-Development-Reported for Angina pectoris in Germany (IV)
- 11 Jun 1996 Investigation in Angina pectoris in Germany (IV)